Chapman Tripp is advising New Zealand healthcare company EBOS Group Ltd. on its proposed $859.8 million purchase of Australian pharmaceuticals wholesaler Symbion Ltd.
EBOS is buying Symbion from The Zuellig Group Inc., a Hong Kong-based investment company, for $679.3 million plus $180.5 million in assumed debt. The transaction is being funded through a combination of cash and the issue of new EBOS shares to Zuellig. After the issue, Zuellig will be a 40 percent shareholder in the enlarged EBOS Group.
The deal, subject to shareholder approval, is expected to close this month.
